Johnson & Johnson has agreed to the divestiture of its entire trauma business in the European Economic Area to remove overlap in trauma devices as a result of the acquisition. On that basis, the Commission cleared the transition.
A likely recipient of the company’s DePuy trauma business is Biomet, which placed a $280 million offer earlier this year.
More Articles on Orthopedic Devices:
Medtronic Launches Power Instruments for Spinal Surgery
Surgeons Report No Improvement in Joint Reconstruction Market
Tornier Consolidates Facilities to Save More Than $2M Per Year
